Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,805 other S bills in the 115th — cohort avg 41d
Budgetary Accuracy in Scoring Interest Costs Act of 2017 or the BASIC Act This bill amends the Congressional Budget and Impoundment Control Act of 1974 to require any cost estimates prepared by the Congressional Budget Office or the Joint Committee on Taxation to include the cost of servicing the public debt.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2017 · third_quarter · Health Issues
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of H.R. 6 - 21st Century Cures (P.L. 114-255). -S.2013 Trickett Wendler Right to Try Act of 2017. -H.R. 2430 and S. 932, FDA Reauthorization Act. -Issues related to Zika vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
Client expense: Not reported · Firm income: $30,000
Read twice and referred to the Committee on the Budget. (text of measure as introduced: CR S2532-2533)
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Health Issues
-Federal funding and regulation of innovative gene therapy technologies -H.R. 2430 and S. 932, FDA Reauthorization Act -H.R. 1268 American Health Care Act and S. ___ Better Care Reconciliation Act -S.2013 Trickett Wendler Right to Try Act of 2017.
Client expense: Not reported · Firm income: $26,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Health Issues
-Federal funding and regulation of innovative gene therapy technologies -H.R. 2430 and S. 932, FDA Reauthorizaiton Act -H.R. 1268 American Health Care Act and S. ___ Better Care Reconciliation Act
Client expense: Not reported · Firm income: $6,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Health Issues
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Re-authorization of the pediatric rare disease priority review voucher.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| WI |